Regents of the University of California’s BioMarin Pharmaceuticals BMRN Stock Holding History

Regents of the University of California’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-9,500	Closed	-$1.18M	–	35
2015 Q1	$1.18M	Hold	9,500	–	–	1.19%	27
2014 Q4	$859K	Buy	+9,500	New	+$790K	0.85%	47

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Regents of the University of California's BMRN Position: Q2 2015 in Review

Regents of the University of California sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2015, closing a stake of 9,500 shares — an estimated $1.18M sold.

Regents of the University of California first reported a position in BMRN in Q4 2014 and held it in 2 quarters. The position peaked at $1.18M in Q1 2015. 392 funds tracked by Wall St. Rank hold BMRN as of Q2 2015.

Regents of the University of California reported no remaining BioMarin Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
Regents of the University of California sold 9,500 BioMarin Pharmaceuticals shares in Q2 2015, an estimated $1.18M.
Regents of the University of California first reported a position in BioMarin Pharmaceuticals in Q4 2014 and held it in 2 quarters.
Regents of the University of California's BioMarin Pharmaceuticals position peaked at $1.18M in Q1 2015.
392 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2015.

Based on Regents of the University of California's 13F filing for Q2 2015, filed 6 Aug 2015.